Zofenopril (calcium)

Zofenopril Calcium (SQ26991) is an orally active angiotensin-converting enzyme (ACE) inhibitor with antioxidant activity and cardioprotective effects. Zofenopril Calcium reduces ROS production and GSH consumption and helps inhibit foam cell formation, thus slowing the progression of atherosclerosis. Zofenopril Calcium prevents cardiac damage caused by chronic Doxorubicin (HY-15142A) [1][2].

Product Specifications

CAS Number

[81938-43-4]

Product Name Alternative

SQ26991

UNSPSC

12352211

Hazard Statement

H302, H361, H372, H410

Target

Angiotensin-converting Enzyme (ACE) ; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Neuroscience-Neurodegeneration

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Zofenopril-calcium.html

Purity

99.76

Solubility

DMSO : 2 mg/mL (ultrasonic)

Smiles

O=C(N(C[C@@H](SC1=CC=CC=C1)C2)[C@@H]2C([O-])=O)[C@H](C)CSC(C3=CC=CC=C3)=O.[0.5Ca2+]

Molecular Formula

C22H22Ca0.5NO4S2

Molecular Weight

448.58

Precautions

H302, H361, H372, H410

References & Citations

[1]Cominacini L, et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens. 2002 Oct;15 (10 Pt 1) :891-5.|[2]Sacco G, et al. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol. 2001 Feb 23;414 (1) :71-8.